Cyclins and cyclin-dependent kinases (CDKs) are key regulators of the cell cycle, and their dysregulation is a common feature in many cancers.
The cell cycle consists of several phases:
G1 Phase (Gap 1): The cell grows and prepares for DNA synthesis.
S Phase (Synthesis): DNA is replicated.
G2 Phase (Gap 2): The cell prepares for mitosis.
M Phase (Mitosis): The cell divides into two daughter cells.
Open menu
Cdh1 and E-cadherin are they the same thing
Cdh1 and E-cadherin refer to the same protein. Cdh1 is the gene that encodes E-cadherin, which is a type of cadherin, a family of proteins involved in cell-cell adhesion. E-cadherin plays a crucial role in maintaining the structure and integrity of tissues by facilitating adhesion between epithelial cells. It is particularly important in the context of development and in the maintenance of epithelial tissue architecture. In summary, Cdh1 is the gene name, while E-cadherin is the protein product of that gene.
CDK1/2/5/9 role in cancer
Cyclin-dependent kinases (CDKs) are a family of protein kinases that play essential roles in regulating the cell cycle, transcription, and other cellular processes. CDK1, CDK2, CDK5, and CDK9 have been implicated in cancer through various mechanisms:
CDK1:
Role: Primarily involved in the regulation of the cell cycle, particularly the transition from G2 phase to mitosis.
Cancer Implication: Overexpression or hyperactivation of CDK1 can lead to uncontrolled cell proliferation and is often associated with various cancers, including breast, colorectal, and lung cancers. CDK1 inhibitors are being explored as potential cancer therapies. CDK2:
Role: Functions mainly in the G1 to S phase transition of the cell cycle, working closely with cyclins D and E.
Cancer Implication: CDK2 is often overexpressed in cancer cells, contributing to tumorigenesis by promoting cell cycle progression. Inhibition of CDK2 has been studied as a therapeutic strategy in cancers such as ovarian and breast cancer. CDK5:
Role: Unlike other CDKs, CDK5 is primarily involved in neuronal function and is activated by p35 and p39. It plays roles in neuronal development and synaptic function.
Cancer Implication: CDK5 has been implicated in certain cancers, particularly in the context of neurodegenerative diseases and brain tumors. Its role in cancer is complex, as it can promote or inhibit tumor growth depending on the context and the specific cancer type. CDK9:
Role: Part of the positive transcription elongation factor b (P-TEFb) complex, CDK9 is involved in regulating transcription by phosphorylating the C-terminal domain of RNA polymerase II.
Cancer Implication: CDK9 is often overexpressed in various cancers, leading to increased transcription of genes that promote cell survival and proliferation. Inhibitors of CDK9 are being investigated as potential cancer therapies, particularly in hematological malignancies.
In summary, CDK1, CDK2, CDK5, and CDK9 each play distinct roles in cell cycle regulation and transcription, and their dysregulation is associated with various cancer types. Targeting these kinases with specific inhibitors is an area of active research in cancer therapy.
CDK4 and CDK6 are cyclin-dependent kinases that play crucial roles in regulating the cell cycle, particularly the transition from the G1 phase to the S phase. Their activity is tightly regulated by cyclins, specifically cyclin D, and they are essential for cell proliferation. Here’s how CDK4 and CDK6 are implicated in cancer:
Role in Cell Cycle Regulation
CDK4/6 Function: CDK4 and CDK6, when activated by cyclin D, phosphorylate the retinoblastoma protein (Rb). This phosphorylation leads to the release of E2F transcription factors, which promote the expression of genes necessary for DNA synthesis and progression into the S phase of the cell cycle.
Implications in Cancer
Overexpression and Dysregulation: In many cancers, CDK4 and CDK6 are often overexpressed or hyperactivated, leading to uncontrolled cell proliferation. This dysregulation can result from various factors, including mutations in cyclins, loss of tumor suppressor genes (like Rb), or amplification of the CDK4/6 genes themselves. Breast Cancer: CDK4/6 is particularly well-studied in hormone receptor-positive breast cancer. In these cancers, the overactivity of CDK4/6 contributes to tumor growth and progression.
Other Cancers: CDK4/6 has also been implicated in other cancers, including melanoma, lung cancer, and certain hematological malignancies. Therapeutic Targeting
CDK4/6 Inhibitors: The discovery of the role of CDK4 and CDK6 in cancer has led to the development of specific inhibitors, such as palbociclib, ribociclib, and abemaciclib. These drugs have shown efficacy in treating hormone receptor-positive breast cancer, often in combination with endocrine therapies (like aromatase inhibitors or tamoxifen).
Mechanism of Action: By inhibiting CDK4/6, these drugs prevent the phosphorylation of Rb, thereby blocking the cell cycle progression from G1 to S phase, leading to reduced cell proliferation and increased apoptosis in cancer cells. Conclusion
CDK4 and CDK6 are critical regulators of the cell cycle, and their dysregulation is a common feature in various cancers. Targeting these kinases with specific inhibitors has become a promising therapeutic strategy, particularly in hormone receptor-positive breast cancer, and ongoing research continues to explore their role in other malignancies.
Cell cycle (CDKs/cyclins) and cancer
The cell cycle is a tightly regulated series of events that lead to cell division and replication. Cyclins and cyclin-dependent kinases (CDKs) are key regulators of the cell cycle, and their dysregulation is a common feature in many cancers. Here’s an overview of how CDKs and cyclins function in the cell cycle and their implications in cancer:
Cell Cycle Phases
The cell cycle consists of several phases:
G1 Phase (Gap 1): The cell grows and prepares for DNA synthesis.
S Phase (Synthesis): DNA is replicated.
G2 Phase (Gap 2): The cell prepares for mitosis.
M Phase (Mitosis): The cell divides into two daughter cells. Role of CDKs and Cyclins
Cyclins: These are regulatory proteins whose levels fluctuate throughout the cell cycle. They activate CDKs by binding to them, forming cyclin-CDK complexes that drive the cell cycle forward.
CDKs: These are serine/threonine kinases that, when activated by cyclins, phosphorylate target proteins to regulate various processes, including:
Progression through the cell cycle.
DNA replication.
Mitotic entry and exit. Key CDKs and Their Functions
CDK1: Regulates the transition from G2 to M phase.
CDK2: Involved in the G1 to S phase transition.
CDK4 and CDK6: Work with cyclin D to promote progression through the G1 phase.
CDK2: Also works with cyclin E to facilitate the G1/S transition.
FRO9: Involved in transcriptional regulation and elongation.
Overexpression: Many cancers exhibit overexpression of cyclins (e.g., cyclin D1) or CDKs (e.g., CDK4/6), leading to uncontrolled cell proliferation.
(Will delete Record if Target field = "Delete") Home